Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood... It is currently being studied for post-ischemic stroke management.
- Mechanism
- Curator reviewed · 1 reference
Azelnidipine inhibits trans-membrane Ca2+ influx through the voltage-dependent channels of smooth muscles in vascular walls. Ca2+ channels are classified into various categories, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels. The L-type Ca2+ channels. Normally, calcium induces smooth muscle contraction, contributing to hypertension. When calcium channels are blocked, the vascular smooth muscle does not contract, resulting in relaxation of vascular smooth muscle walls and decreased blood pressure.
- Primary indication
- For the treatment of hypertension.Curator reviewed
- Formula / weight
- C33H34N4O6 · 582.657 g/mol (avg)
- Code names
- CS-905
Resolves to
ZKFQEACEUNWPMT-UHFFFAOYSA-NSMILESCC(C)OC(=O)C1=C(C)NC(N)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC1CN(C1)C(C1=CC=CC=C1)C1=CC=CC=C1What you can answer from here — as of June 15, 2026
Which drugs share a target with Azelnidipine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account